About
Shop Products
Contract Services
Resources
Contact
New Products

Prophylactic treatment with antagonistic anti-TNFα antibodies may improve outcomes of anti-PD-1 and anti-CTLA-4 combination cancer immunotherapy

Follow Us

Posted on June 11, 2019

More Posts

Product
Product Highlights
Research
Publication Highlights

Follow Us

Contact

enquiries@bxcell.sg

48 Toh Guan Road East
#04-138 Enterprise Hub
Singapore 608586

The Latest & Greatest

Hot Immunotherapy Target: OX40
Type I IFN Exacerbates Disease in Tuberculosis Susceptible Mice by Inducing Neutrophil-mediated Lung Inflammation and NETosis
Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression
Immunocytokines are a promising immunotherapeutic approach against glioblastoma

Information

About
Shop Products
Contract Services
FAQs
Contact

Legal Disclaimer
Privacy Policy

Copyright © 2020 Bio X Cell All Rights Reserved.

LOADING